The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector for initiating treatment in early Alzheimer’s disease, expanding at-home care options.
Written By: Mayuresh Salvi, PharmD
Reviewed By: Pharmacally Editorial Team
Eisai and Biogen have received U.S. Food and Drug Administration approval for a supplemental Biologics License Application covering LEQEMBI IQLIK® (lecanemab-irmb), a once-weekly subcutaneous autoinjector for the initiation of treatment in adults with early Alzheimer’s disease. The approval marks the first anti-amyloid therapy globally to support at-home dosing from treatment initiation through maintenance, providing patients with an alternative to intravenous (IV) infusions.
The approval follows the FDA’s three-month extension of the Priority Review in May 2026 after the agency requested additional information that was classified as a major amendment to the supplemental Biologics License Application (sBLA). At the time, Eisai and Biogen said the FDA had not raised concerns about the application’s approvability.
LEQEMBI is approved in the United States for adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease, collectively referred to as early Alzheimer’s disease. The newly approved regimen consists of 500 mg administered once weekly as two 250 mg injections, each delivered in approximately 15 seconds using an autoinjector. After 18 months of treatment, patients may transition to a 360 mg once-weekly maintenance dose administered subcutaneously. Patients can switch between IV infusion and subcutaneous administration at any stage of therapy.
Scientific and Clinical Context
Lecanemab is a monoclonal antibody that selectively targets aggregated amyloid-beta protofibrils, a key pathological feature of Alzheimer’s disease. By reducing amyloid plaque accumulation in the brain, the therapy aims to slow disease progression during the earliest symptomatic stages, when intervention is expected to provide the greatest clinical benefit.
The availability of a self-administered formulation may reduce dependence on infusion centers and improve treatment accessibility for patients and caregivers while preserving infusion capacity for those who continue to require intravenous therapy.
Clinical Evidence Supporting Approval
The FDA based its decision on a comprehensive clinical package evaluating subcutaneous administration across multiple studies, including sub-studies from the Phase 3 Clarity AD long-term extension (LTE) (NCT03887455), which followed participants after the 18-month core trial in patients with early Alzheimer’s disease.
The studies showed that once-weekly subcutaneous administration achieved drug exposure comparable to intravenous dosing, supporting similar clinical efficacy and amyloid removal. Safety findings also remained consistent with the established IV formulation.
The incidence of exposure-related adverse events, including amyloid-related imaging abnormalities with edema (ARIA-E), was expected to be comparable between subcutaneous and intravenous administration. Investigators also reported no increase in isolated ARIA-H compared with placebo. Injection-related reactions occurred with subcutaneous dosing but were generally localized, while systemic reactions were reported less frequently.
Expanding Treatment Options
Howard Fillit, MD, Co-Founder and Chief Science Officer Emeritus of the Alzheimer’s Drug Discovery Foundation, said the approval provides patients and care partners with greater flexibility in selecting how anti-amyloid therapy is delivered. He noted that advances in drug delivery could improve treatment access and support future precision medicine approaches in Alzheimer’s disease.
An autoinjector usability study involving 50 patients with early Alzheimer’s disease and 50 caregivers also found that 94% of participants considered the device easy to use after evaluating a training version of the injector.
Commercial Launch and Patient Support
LEQEMBI IQLIK for initiation dosing is expected to become available in the United States in late August 2026 through specialty pharmacies. Eisai’s LEQEMBI Companion program will continue to provide insurance navigation, copay assistance for eligible patients, and access to the company’s Patient Assistance Program for qualifying uninsured individuals.
Eisai leads the global development and regulatory strategy for lecanemab, while Eisai and Biogen jointly commercialize the therapy in the United States. The latest approval broadens administration options across the full treatment course and may help expand access to anti-amyloid therapy for eligible patients with early Alzheimer’s disease.
What This Means for Patients
For people living with early Alzheimer’s disease, the approval of LEQEMBI IQLIK expands how anti-amyloid treatment can be received. Eligible patients can now begin therapy with a once-weekly subcutaneous autoinjector instead of starting with intravenous infusions, allowing treatment to be administered at home under the supervision of a healthcare provider or trained caregiver, when appropriate.
The new option may reduce the need for frequent visits to infusion centers, shorten treatment time, and ease the logistical burden on patients and caregivers. Patients also retain the flexibility to switch between subcutaneous injections and intravenous infusions during treatment based on clinical needs or personal preference, while maintaining access to the same disease-modifying therapy.
Reference
About the Writer
Mayuresh Sunil Salvi (Linkedin) is a PharmD professional and healthcare writer with a strong interest in pharmacovigilance, drug safety, and emerging medical research. He is passionate about exploring new drug discoveries, clinical research, and advances in evidence-based medicine. His interests also include ward rounds, prescription audits, and treatment analysis to support rational pharmacotherapy and improved patient care.